Vividion Therapeutics Acquires Tavros Therapeutics

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging innovative discovery technologies to reveal high-value, traditionally undruggable targets and create small molecule precision therapeutics for severe cancers and immune disorders, has announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a fully owned and autonomously functioning subsidiary of Bayer AG.

The inclusion of Tavros significantly enhances Vividion’s functional genomics knowledge and abilities, introducing unique techniques for genomic screening that can discover new target possibilities and assist in discovery and translational initiatives focused on known targets. Integrating the Tavros platform with Vividion’s proficiency and skills in chemoproteomics will significantly boost Vividion’s initiatives to produce possible best- and first-in-class drug targets in oncology and immunology.

Vividion and Tavros have collaborated for two years in a strategic partnership aimed at discovering and developing innovative precision therapeutics that target cancer-causing proteins which traditional small molecule drugs have failed to address.

“The addition of Tavros will expand and strengthen our chemoproteomics drug screening capabilities and open up a new target space to fuel the growing pipeline of novel therapies across oncology and immunology,” said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. “We have already seen the power of combining Vividion’s platform and compound library with Tavros’s functional genomics capabilities in uncovering druggable vulnerabilities in tumor cells. We are excited to take this next step to unlock the full potential of our work together for the patients in need.”